SCHEMBL3750271

SCHEMBL3750271

COc1ccc2c(c1OC)C(=O)N(Cc1ccc(F)c(F)c1)C2C(=O)NCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 2/20 0.49
WDR77 Q9BQA1 2/20 0.49
CTSD P07339 5/20 0.46
SCN5A Q14524 2/20 0.45
SCN9A Q15858 2/20 0.45
TP53 P04637 1/20 0.45
HCRTR2 O43614 2/20 0.43
ALDH1A1 P00352 3/20 0.43
POLB P06746 1/20 0.43
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KCNH2 Q12809 2/20 0.42
KCNA5 P22460 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3750823 0.79 PRMT5 (0.61) PRMT5WDR77SCN5ASCN9AALDH1A1
SCHEMBL3756522 0.78 KCNA5 (0.52) PRMT5WDR77CTSDSCN5ASCN9A
SCHEMBL3747728 0.76 KCNA5 (0.53) PRMT5WDR77SCN5ASCN9AKCNH2
SCHEMBL3750321 0.75 KCNA5 (0.48) CTSDSCN5ASCN9AALDH1A1SMN1; SMN2
SCHEMBL3754019 0.74 KCNA5 (0.55) TP53ALDH1A1LMNASMN1; SMN2KCNH2
SCHEMBL3761064 0.74 PRMT5 (0.59) PRMT5WDR77SCN5ASCN9AKCNH2
SCHEMBL3758616 0.73 KCNA5 (0.51) PRMT5WDR77SCN5ASCN9AALDH1A1
SCHEMBL3751901 0.73 PRMT5 (0.56) PRMT5WDR77SCN5ASCN9ATP53
SCHEMBL3751530 0.73 KCNA5 (0.46) SCN5ASCN9ATP53ALDH1A1POLB
SCHEMBL3756788 0.72 ACHE (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 PRMT5 1341/4885WDR77 2402/4885CTSD 4406/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 PRMT5 683/4885WDR77 2954/4885CTSD 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.